| abstract |
The composition, which is comprised of at least two antibodies, preferably monoclonal antibodies directed against the interleukin-2 receiver, includes an anti-p55 antibody and an anti-p75 antibody providing for the inhibition of the binding of interleukin-2 to its receiver. It concerns particularly the pairs 33B3.1/TU27, 33B3.1/Tic and 33B3.1/A41. The composition is useful as active agent against rejection of members and marrow grafting, against leucemia and positive CD25 lymphomas as well as against auto-immune pathologies such as type 1 diabetes, rheumatoid polyarthritis, ankylosing spondylarthritis, multiple sclerosis and myasthenia gravis. |